MedWatch

Small Danish biotech firm to advise US authorities: "It opens a lot of doors"

The young Danish biotech company Cobo Technologies will advise the FDA on clinical trials with the genome editing tool CRISPR. The company's proprietary product can potentially become the standard quality control of CRISPR-based treatments.

Photo: Cobo Technologies

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles